IP Library Granted Patent US 9,586,046
Granted Patent B2
US 9,586,046 · App. 14/480,242 · Granted Mar 7, 2017

Electrode band system and methods of using the system to treat obesity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,586,046
App. No.
14/480,242
Granted
Mar 7, 2017
Kind
B2
Abstract

At least one of a plurality of disorders of a patient characterized at least in part by vagal activity innervating at least one of a plurality of organs of the patient is treated by a method that includes positioning an electrode on a vagus nerve. An electrical signal is applied to the electrode to modulate vagal activity by an amount selected to treat the disorder. In some embodiments, the disorder is obesity. The signal may be a blocking or a stimulation signal. In some embodiments, the signal is selected to, at least in part, downregulate neural activity on the vagus nerve.

Claims (7)

1. A system for treating obesity comprising:

a) a posterior electrode and an anterior electrode adapted to be placed on a vagus nerve at a subdiaphragmatic location;

b) an implantable controller electrically connected to each of the posterior electrode and anterior electrode; the implantable controller comprising an induction coil, an anterior and a posterior electrical signal generator, a battery, and a central processing unit comprising program storage and memory;

c) an external controller comprising an external coil inductively coupled to the induction coil, wherein the external controller is configured to communicate at least one parameter for a neural conduction blocking signal to the implantable controller, wherein the at least one parameter is selected for the neural conduction blocking signal to i) at least partially downregulate the vagus nerve, ii) allow at least partial recovery of the nerve activity following discontinuation of the neural conduction blocking signal, and iii) reduce pancreatic and biliary output via inhibition of pancreo-biliary output.

2. The system of claim 1 , wherein the parameter is a frequency of at least 500 Hz.

3. The system of claim 2 , wherein the parameter is application of the signal intermittently.

4. The system of claim 1 , wherein the central processing unit stores the at least one parameter.

Assignments (2)
SECURITY INTEREST Recorded Jun 19, 2020
From: RESHAPE LIFESCIENCES INC.; RESHAPE MEDICAL LLC
To: ARMISTICE CAPITAL MASTER FUND LTD.
Reel/Frame 052987/0463 →
CHANGE OF NAME Recorded Mar 30, 2018
From: ENTEROMEDICS INC.
To: RESHAPE LIFESCIENCES INC.
Reel/Frame 045949/0495 →